跳转至内容
Merck

SML0216

Sigma-Aldrich

布林佐胺

≥98% (HPLC)

别名:

AL 4862, (5R)-5-乙基氨基-3-(3-甲氧基丙基)-2,2-二氧代-2?6,9-二硫杂-3-氮杂双环[4.3.0]壬-7,10-二烯-8-磺酰胺, (R)-4-(乙基氨基)-3,4-二氢-2-(3-甲氧基丙基)-2H-噻吩并[3,2-e] -1,2-噻嗪-6-磺酰胺1,1-二氧化物

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C12H21N3O5S3
分子量:
383.51
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to beige

溶解性

DMSO: ≥10 mg/mL

储存温度

−20°C

SMILES字符串

CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O

InChI

1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1

InChI key

HCRKCZRJWPKOAR-JTQLQIEISA-N

基因信息

human ... CA2(760)

正在寻找类似产品? 访问 产品对比指南

一般描述

布林佐胺是一种小分子量的化合物,能结合黑色素。该药可用于眼部治疗。

应用

在黑色素结合测定中,布林佐胺已被用作黑色素结合化合物或药物。它也被用作碳酸酐酶抑制剂(CAI)。

生化/生理作用

布林佐胺是一种用于降低眼压的碳酸酐酶 II 抑制剂。
布林佐胺是碳酸酐酶 II 抑制剂

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Rajendra S Kadam et al.
Drug metabolism and disposition: the biological fate of chemicals, 39(9), 1529-1537 (2011-06-16)
Ophthalmic carbonic anhydrase inhibitors have been shown to improve retinal and optic nerve blood flow. However, the relative tissue distributions of commercially available carbonic anhydrase inhibitors to the optic nerve are not known. The objective of this study was to
Risto S Cvetkovic et al.
Drugs & aging, 20(12), 919-947 (2003-10-21)
Brinzolamide is a highly specific carbonic anhydrase (CA) inhibitor which lowers intraocular pressure (IOP) by reducing the rate of aqueous humour formation. Formulated as a 1% ophthalmic suspension (Azopt) and administered twice or three times daily, brinzolamide is indicated for
James F T Li Yim et al.
Current medical research and opinion, 27(8), 1499-1502 (2011-06-10)
To determine the intraocular pressure (IOP) lowering effect of brinzolamide when added to latanoprost. Patients who were simultaneously on brinzolamide and latanoprost were identified from the large prospective database of patients diagnosed with primary open angle glaucoma, normal tension glaucoma
L DeSantis
Survey of ophthalmology, 44 Suppl 2, S119-S129 (2000-02-09)
The development of topically active carbonic anhydrase inhibitors (CAIs) is a significant recent achievement in glaucoma medical treatment. Brinzolamide, the newest topical CAI, exhibits selectivity, high affinity, and potent inhibitory activity for the carbonic anhydrase type II isozyme (CA-II), which
Ivan Goldberg et al.
Journal of glaucoma, 21(1), 55-59 (2010-11-05)
To compare the efficacy of brinzolamide versus placebo when added to travoprost/timolol fixed combination (TTFC) in uncontrolled patients. This was a prospective, double-masked, randomized, placebo-controlled, parallel comparison of ocular hypertensive or primary open-angle glaucoma patients. Patients treated with a prostaglandin-based

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门